Several AI-driven innovations are propelling biotech forward. CSPC Pharmaceutical and AstraZeneca launched a $5.3 billion preclinical drug R&D collaboration leveraging CSPC’s AI drug discovery platform. Scope Biosciences secured €1 million to scale its CRISPR-based molecular diagnostics platform for ultra-precise detection. Additionally, NextCure inked a $745 million antibody-drug conjugate deal with Simcere Zaiming, enhancing cancer therapy pipelines. Furthermore, advances in machine learning have yielded more accurate inverse protein folding methods, aiding drug design. These developments underscore the growing integration of AI and machine learning in pharmaceutical research and precision diagnostics.